- Home
- COYA vs MGX Comparison
COYA vs MGX Comparison
Compare COYA & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- MGX
- Stock Information
- Founded
- COYA 2020
- MGX 2018
- Country
- COYA United States
- MGX United States
- Employees
- COYA N/A
- MGX N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- MGX
- Sector
- COYA Health Care
- MGX
- Exchange
- COYA Nasdaq
- MGX NYSE
- Market Cap
- COYA 98.5M
- MGX 87.0M
- IPO Year
- COYA 2022
- MGX 2024
- Fundamental
- Price
- COYA $6.48
- MGX $1.91
- Analyst Decision
- COYA Strong Buy
- MGX Strong Buy
- Analyst Count
- COYA 4
- MGX 4
- Target Price
- COYA $16.25
- MGX $13.00
- AVG Volume (30 Days)
- COYA 143.6K
- MGX 420.9K
- Earning Date
- COYA 05-08-2025
- MGX 03-18-2025
- Dividend Yield
- COYA N/A
- MGX N/A
- EPS Growth
- COYA N/A
- MGX N/A
- EPS
- COYA N/A
- MGX N/A
- Revenue
- COYA $9,554,315.00
- MGX $55,080,000.00
- Revenue This Year
- COYA N/A
- MGX $16.92
- Revenue Next Year
- COYA $56.22
- MGX N/A
- P/E Ratio
- COYA N/A
- MGX N/A
- Revenue Growth
- COYA N/A
- MGX 45.13
- 52 Week Low
- COYA $4.75
- MGX $1.61
- 52 Week High
- COYA $10.69
- MGX $11.86
- Technical
- Relative Strength Index (RSI)
- COYA 49.74
- MGX 36.49
- Support Level
- COYA $6.21
- MGX $1.87
- Resistance Level
- COYA $6.96
- MGX $2.08
- Average True Range (ATR)
- COYA 0.69
- MGX 0.15
- MACD
- COYA -0.03
- MGX 0.01
- Stochastic Oscillator
- COYA 27.16
- MGX 15.52
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).